Cassava Sciences, Inc. (SAVA) 10-Year Financial Performance & Capital Metrics

SAVA • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

AboutCassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.Show more

Revenue $0
EBITDA -$140M -34.4%
Net Income -$24M +75.0%
EPS (Diluted) -0.52 +77.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -17.19% +67.7%
ROIC -634.06% -71.5%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.7x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 11.1% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-500.27%

EPS CAGR

10Y-

5Y-

3Y-

TTM-58.7%

ROCE

10Y Avg-47.81%

5Y Avg-44.26%

3Y Avg-63.7%

Latest-99.87%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	45K	58K	68K	69K	1.57M	3.05M	0	68.03M	89.42M	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-45K	-58K	-68K	-69K	-1.57M	-3.05M	0	-68.03M	-89.42M	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-5.16%	-0.29%	-0.17%	-0.01%	-21.72%	-0.95%	1%	-	-0.31%	1%
Operating Expenses+	14.2M	14.96M	11.95M	6.66M	3.39M	3.39M	32.87M	11.99M	16.53M	141.45M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	5.1M	5.78M	4.33M	3.69M	3.39M	3.74M	8.05M	11.99M	16.53M	71.81M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	9.1M	9.18M	7.62M	2.97M	6.3M	7.25M	24.81M	68.93M	89.42M	69.64M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	-6.3M	-7.6M	0	-68.93M	-89.42M	0
Operating Income+	-14.2M	-14.96M	-11.95M	-6.66M	-4.96M	-6.45M	-32.87M	-80.02M	-105.96M	-141.45M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.14%	-0.05%	0.2%	0.44%	0.26%	-0.3%	-4.1%	-1.43%	-0.32%	-0.33%
EBITDA+	-14.16M	-14.9M	-11.88M	-6.59M	-4.9M	-6.42M	-32.33M	-78.72M	-104.43M	-140.31M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.14%	-0.05%	0.2%	0.45%	0.26%	-0.31%	-4.03%	-1.43%	-0.33%	-0.34%
D&A (Non-Cash Add-back)	45K	58K	68K	69K	58K	22K	534K	1.3M	1.53M	1.13M
EBIT	-14.14M	-14.85M	-11.91M	-6.56M	-4.96M	-6.79M	-32.87M	-80.02M	-105.96M	-142.28M
Net Interest Income+	0	0	0	0	328K	112K	49K	2.78M	7.83M	8.51M
Interest Income	57K	107K	38K	105K	328K	112K	49K	2.78M	7.83M	8.51M
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	57K	107K	38K	105K	328K	112K	483K	3.77M	8.74M	117.1M
Pretax Income+	-14.14M	-14.85M	-11.91M	-6.56M	-4.63M	-6.33M	-32.38M	-76.25M	-97.22M	-24.34M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	-57K	-107K	-38K	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-14.14M	-14.85M	-11.91M	-6.56M	-4.63M	-6.33M	-32.38M	-76.25M	-97.22M	-24.34M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.14%	-0.05%	0.2%	0.45%	0.29%	-0.37%	-4.11%	-1.35%	-0.28%	0.75%
Net Income (Continuing)	-14.14M	-14.85M	-11.91M	-6.56M	-4.63M	-6.33M	-32.38M	-76.25M	-97.22M	-24.34M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.16	-2.28	-1.82	-0.61	-0.24	-0.22	-0.81	-1.80	-2.32	-0.52
EPS Growth %	-0.13%	-0.06%	0.2%	0.66%	0.61%	0.08%	-2.68%	-1.22%	-0.29%	0.78%
EPS (Basic)	-2.16	-2.28	-1.82	-0.61	-0.24	-0.22	-0.81	-1.80	-2.32	-0.53
Diluted Shares Outstanding	6.54M	6.52M	6.54M	10.68M	17.41M	26.11M	39.41M	40.2M	41.93M	46.6M
Basic Shares Outstanding	6.54M	6.52M	6.54M	10.68M	17.41M	26.11M	39.41M	40.2M	41.93M	46.33M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	31.69M	19.07M	10.66M	20.04M	23.35M	93.99M	244.48M	211.23M	129.63M	136.53M
Cash & Short-Term Investments	31.3M	18.71M	10.48M	19.81M	23.08M	93.51M	233.44M	201.01M	121.14M	128.57M
Cash Only	31.3M	18.71M	10.48M	19.81M	23.08M	93.51M	233.44M	201.01M	121.14M	128.57M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	962K	947K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	392K	356K	184K	233K	268K	31K	10.38M	160K	6.78M	6.21M
Total Non-Current Assets+	227K	232K	168K	99K	137K	306K	22.3M	23.61M	22.03M	21M
Property, Plant & Equipment	200K	300K	200K	100K	137K	306K	20.83M	22.99M	21.85M	20.96M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	1.07M	622K	176K	37K
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	27K	-68K	-32K	-1K	0	0	399K	0	0	0
Total Assets+	31.92M	19.3M	10.83M	20.14M	23.49M	94.3M	266.78M	234.83M	151.66M	157.53M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.22%	-0.4%	-0.44%	0.86%	0.17%	3.02%	1.83%	-0.12%	-0.35%	0.04%
Total Current Liabilities+	2.55M	665K	1.13M	511K	1.39M	1.86M	12.53M	7.06M	14.2M	11.75M
Accounts Payable	1.03M	303K	424K	294K	453K	911K	7.13M	4.02M	10.57M	7.65M
Days Payables Outstanding	8.39K	1.91K	2.28K	1.56K	105.45	108.91	-	21.55	43.16	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	894K	27K	399K	156K	67K	177K	631K	662K	3.42M	45K
Current Ratio	12.42x	28.68x	9.42x	39.22x	16.83x	50.40x	19.51x	29.91x	9.13x	11.62x
Quick Ratio	12.42x	28.68x	9.42x	39.22x	16.83x	50.40x	19.51x	29.91x	9.13x	11.62x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1.03M	303K	424K	294K	0	235K	333K	232K	0	79K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	235K	139K	35K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	194K	197K	0	79K
Total Liabilities	2.55M	665K	1.13M	511K	1.39M	2.1M	12.87M	7.29M	14.2M	11.83M
Total Debt+	0	0	0	0	90K	293K	236K	139K	0	0
Net Debt	-31.3M	-18.71M	-10.48M	-19.81M	-22.99M	-93.21M	-233.2M	-200.88M	-121.14M	-128.57M
Debt / Equity	-	-	-	-	0.00x	0.00x	0.00x	0.00x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	29.37M	18.64M	9.7M	19.63M	22.1M	92.2M	253.91M	227.54M	137.47M	145.7M
Equity Growth %	-0.27%	-0.37%	-0.48%	1.02%	0.13%	3.17%	1.75%	-0.1%	-0.4%	0.06%
Book Value per Share	4.49	2.86	1.48	1.84	1.27	3.53	6.44	5.66	3.28	3.13
Total Shareholders' Equity	29.37M	18.64M	9.7M	19.63M	22.1M	92.2M	253.91M	227.54M	137.47M	145.7M
Common Stock	46K	46K	7K	17K	22K	35K	40K	42K	42K	48K
Retained Earnings	-130.64M	-145.49M	-157.4M	-163.96M	-168.59M	-174.92M	-207.31M	-283.55M	-380.77M	-405.11M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-700K	-700K	-800K	-900K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-9.05M	-12.23M	-8.24M	-4.77M	-2.51M	-5.38M	-30.2M	-77.51M	-82.03M	-116.93M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	0.05%	-0.35%	0.33%	0.42%	0.47%	-1.14%	-4.61%	-1.57%	-0.06%	-0.43%
Net Income	-14.14M	-14.85M	-11.91M	-6.56M	-4.63M	-6.33M	-32.38M	-76.25M	-97.22M	-24.34M
Depreciation & Amortization	45K	58K	68K	69K	58K	22K	534K	1.3M	1.53M	1.13M
Stock-Based Compensation	3.46M	4.33M	2.97M	2.39M	0	988K	1.76M	2.07M	0	16.29M
Deferred Taxes	0	0	0	0	0	0	3.39M	-8.12M	0	0
Other Non-Cash Items	-4K	-8K	-2K	2.66M	1.3M	-346K	-3.39M	8.12M	4.59M	-108.18M
Working Capital Changes	1.59M	-1.77M	635K	-670K	763K	288K	-104K	-4.63M	9.08M	-1.83M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	841K	-711K	129K	-130K	159K	458K	6.21M	-3.45M	6.9M	-2.92M
Cash from Investing+	-192K	-2.17M	2.1M	0	-18K	360K	-22.21M	-2.71M	-414K	-103K
Capital Expenditures	-195K	-75K	0	0	-18K	0	-22.21M	-2.71M	-414K	-103K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	3	-2.09K	2.1K	0	0	360K	0	0	0	0
Cash from Financing+	-46K	-284K	0	14.1M	5.81M	75.45M	192.34M	47.8M	2.56M	124.47M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-46K	-284K	0	0	0	256K	2.52M	475K	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.25M	-12.31M	-8.24M	-4.77M	-2.53M	-5.38M	-52.41M	-80.23M	-82.44M	-117.03M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	0.04%	-0.33%	0.33%	0.42%	0.47%	-1.13%	-8.74%	-0.53%	-0.03%	-0.42%
FCF per Share	-1.41	-1.89	-1.26	-0.45	-0.15	-0.21	-1.33	-2.00	-1.97	-2.51
FCF Conversion (FCF/Net Income)	0.64x	0.82x	0.69x	0.73x	0.54x	0.85x	0.93x	1.02x	0.84x	4.80x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-40.75%	-61.87%	-84.07%	-44.72%	-22.2%	-11.08%	-18.71%	-31.67%	-53.27%	-17.19%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-250.25%	-253.35%	-369.66%	-634.06%
Debt / Equity	-	-	-	-	0.00x	0.00x	0.00x	0.00x	-	-
FCF Conversion	0.64x	0.82x	0.69x	0.73x	0.54x	0.85x	0.93x	1.02x	0.84x	4.80x

Frequently Asked Questions

Growth & Financials

Cassava Sciences, Inc. (SAVA) grew revenue by 0.0% over the past year. Growth has been modest.

Cassava Sciences, Inc. (SAVA) reported a net loss of $106.0M for fiscal year 2024.

Dividend & Returns

Cassava Sciences, Inc. (SAVA) has a return on equity (ROE) of -17.2%. Negative ROE indicates the company is unprofitable.

Cassava Sciences, Inc. (SAVA) had negative free cash flow of $83.9M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Cassava Sciences, Inc. (SAVA) 10-Year Financial Performance & Capital Metrics

SAVA • • Industrial / General

HealthcareBiotechnologyNeurology & CNS DisordersAlzheimer's & Neurodegenerative

Revenue $0
EBITDA -$140M -34.4%
Net Income -$24M +75.0%
EPS (Diluted) -0.52 +77.6%
Gross Margin -
EBITDA Margin -
Operating Margin -
Net Margin -
ROE -17.19% +67.7%
ROIC -634.06% -71.5%
Debt/Equity -
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓High quality earnings: Operating CF exceeds net income
✓Trading at only 0.7x book value

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Shares diluted 11.1% in last year
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y-

3Y-

TTM-

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-500.27%

EPS CAGR

10Y-

5Y-

3Y-

TTM-58.7%

ROCE

10Y Avg-47.81%

5Y Avg-44.26%

3Y Avg-63.7%

Latest-99.87%

Peer Comparison

Alzheimer's & Neurodegenerative

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
ANVSAnnovis Bio, Inc.	84.81M	3.20	-0.00			-189.15%
CLNNClene Inc.	60.19M	5.11	-0.90	-47.71%	-142.5%	-17.38%
ABOSAcumen Pharmaceuticals, Inc.	112.67M	1.86	-1.09			-143.12%	0.16
BHVNBiohaven Ltd.	1.58B	11.92	-1.28			-198.83%	0.09
IKTInhibikase Therapeutics, Inc.	200.09M	1.65	-1.42	-100%		-65.37%	0.00
ALECAlector, Inc.	198.66M	1.82	-1.48	3.6%	-156.03%	-186.68%	0.34
CGTXCognition Therapeutics, Inc.	121.82M	1.38	-1.62			-76.61%	0.04
ATHEAlterity Therapeutics Limited	60M	3.31	-2.90	35.32%	-330.63%	-73.75%	0.00

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	0	0	0	0	0	0	0	0	0	0
Revenue Growth %	-	-	-	-	-	-	-	-	-	-
Cost of Goods Sold+	45K	58K	68K	69K	1.57M	3.05M	0	68.03M	89.42M	0
COGS % of Revenue	-	-	-	-	-	-	-	-	-	-
Gross Profit+	-45K	-58K	-68K	-69K	-1.57M	-3.05M	0	-68.03M	-89.42M	0
Gross Margin %	-	-	-	-	-	-	-	-	-	-
Gross Profit Growth %	-5.16%	-0.29%	-0.17%	-0.01%	-21.72%	-0.95%	1%	-	-0.31%	1%
Operating Expenses+	14.2M	14.96M	11.95M	6.66M	3.39M	3.39M	32.87M	11.99M	16.53M	141.45M
OpEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Selling, General & Admin	5.1M	5.78M	4.33M	3.69M	3.39M	3.74M	8.05M	11.99M	16.53M	71.81M
SG&A % of Revenue	-	-	-	-	-	-	-	-	-	-
Research & Development	9.1M	9.18M	7.62M	2.97M	6.3M	7.25M	24.81M	68.93M	89.42M	69.64M
R&D % of Revenue	-	-	-	-	-	-	-	-	-	-
Other Operating Expenses	0	0	0	0	-6.3M	-7.6M	0	-68.93M	-89.42M	0
Operating Income+	-14.2M	-14.96M	-11.95M	-6.66M	-4.96M	-6.45M	-32.87M	-80.02M	-105.96M	-141.45M
Operating Margin %	-	-	-	-	-	-	-	-	-	-
Operating Income Growth %	-0.14%	-0.05%	0.2%	0.44%	0.26%	-0.3%	-4.1%	-1.43%	-0.32%	-0.33%
EBITDA+	-14.16M	-14.9M	-11.88M	-6.59M	-4.9M	-6.42M	-32.33M	-78.72M	-104.43M	-140.31M
EBITDA Margin %	-	-	-	-	-	-	-	-	-	-
EBITDA Growth %	-0.14%	-0.05%	0.2%	0.45%	0.26%	-0.31%	-4.03%	-1.43%	-0.33%	-0.34%
D&A (Non-Cash Add-back)	45K	58K	68K	69K	58K	22K	534K	1.3M	1.53M	1.13M
EBIT	-14.14M	-14.85M	-11.91M	-6.56M	-4.96M	-6.79M	-32.87M	-80.02M	-105.96M	-142.28M
Net Interest Income+	0	0	0	0	328K	112K	49K	2.78M	7.83M	8.51M
Interest Income	57K	107K	38K	105K	328K	112K	49K	2.78M	7.83M	8.51M
Interest Expense	0	0	0	0	0	0	0	0	0	0
Other Income/Expense	57K	107K	38K	105K	328K	112K	483K	3.77M	8.74M	117.1M
Pretax Income+	-14.14M	-14.85M	-11.91M	-6.56M	-4.63M	-6.33M	-32.38M	-76.25M	-97.22M	-24.34M
Pretax Margin %	-	-	-	-	-	-	-	-	-	-
Income Tax+	-57K	-107K	-38K	0	0	0	0	0	0	0
Effective Tax Rate %	1%	1%	1%	1%	1%	1%	1%	1%	1%	1%
Net Income+	-14.14M	-14.85M	-11.91M	-6.56M	-4.63M	-6.33M	-32.38M	-76.25M	-97.22M	-24.34M
Net Margin %	-	-	-	-	-	-	-	-	-	-
Net Income Growth %	-0.14%	-0.05%	0.2%	0.45%	0.29%	-0.37%	-4.11%	-1.35%	-0.28%	0.75%
Net Income (Continuing)	-14.14M	-14.85M	-11.91M	-6.56M	-4.63M	-6.33M	-32.38M	-76.25M	-97.22M	-24.34M
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-2.16	-2.28	-1.82	-0.61	-0.24	-0.22	-0.81	-1.80	-2.32	-0.52
EPS Growth %	-0.13%	-0.06%	0.2%	0.66%	0.61%	0.08%	-2.68%	-1.22%	-0.29%	0.78%
EPS (Basic)	-2.16	-2.28	-1.82	-0.61	-0.24	-0.22	-0.81	-1.80	-2.32	-0.53
Diluted Shares Outstanding	6.54M	6.52M	6.54M	10.68M	17.41M	26.11M	39.41M	40.2M	41.93M	46.6M
Basic Shares Outstanding	6.54M	6.52M	6.54M	10.68M	17.41M	26.11M	39.41M	40.2M	41.93M	46.33M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	31.69M	19.07M	10.66M	20.04M	23.35M	93.99M	244.48M	211.23M	129.63M	136.53M
Cash & Short-Term Investments	31.3M	18.71M	10.48M	19.81M	23.08M	93.51M	233.44M	201.01M	121.14M	128.57M
Cash Only	31.3M	18.71M	10.48M	19.81M	23.08M	93.51M	233.44M	201.01M	121.14M	128.57M
Short-Term Investments	0	0	0	0	0	0	0	0	0	0
Accounts Receivable	0	0	0	0	0	0	0	0	962K	947K
Days Sales Outstanding	-	-	-	-	-	-	-	-	-	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	392K	356K	184K	233K	268K	31K	10.38M	160K	6.78M	6.21M
Total Non-Current Assets+	227K	232K	168K	99K	137K	306K	22.3M	23.61M	22.03M	21M
Property, Plant & Equipment	200K	300K	200K	100K	137K	306K	20.83M	22.99M	21.85M	20.96M
Fixed Asset Turnover	-	-	-	-	-	-	-	-	-	-
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	0	0	0	0	0	0	1.07M	622K	176K	37K
Long-Term Investments	0	0	0	0	0	0	0	0	0	0
Other Non-Current Assets	27K	-68K	-32K	-1K	0	0	399K	0	0	0
Total Assets+	31.92M	19.3M	10.83M	20.14M	23.49M	94.3M	266.78M	234.83M	151.66M	157.53M
Asset Turnover	-	-	-	-	-	-	-	-	-	-
Asset Growth %	-0.22%	-0.4%	-0.44%	0.86%	0.17%	3.02%	1.83%	-0.12%	-0.35%	0.04%
Total Current Liabilities+	2.55M	665K	1.13M	511K	1.39M	1.86M	12.53M	7.06M	14.2M	11.75M
Accounts Payable	1.03M	303K	424K	294K	453K	911K	7.13M	4.02M	10.57M	7.65M
Days Payables Outstanding	8.39K	1.91K	2.28K	1.56K	105.45	108.91	-	21.55	43.16	-
Short-Term Debt	0	0	0	0	0	0	0	0	0	0
Deferred Revenue (Current)	0	0	0	0	0	0	0	0	0	0
Other Current Liabilities	894K	27K	399K	156K	67K	177K	631K	662K	3.42M	45K
Current Ratio	12.42x	28.68x	9.42x	39.22x	16.83x	50.40x	19.51x	29.91x	9.13x	11.62x
Quick Ratio	12.42x	28.68x	9.42x	39.22x	16.83x	50.40x	19.51x	29.91x	9.13x	11.62x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	1.03M	303K	424K	294K	0	235K	333K	232K	0	79K
Long-Term Debt	0	0	0	0	0	0	0	0	0	0
Capital Lease Obligations	0	0	0	0	0	235K	139K	35K	0	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	0	0	0	194K	197K	0	79K
Total Liabilities	2.55M	665K	1.13M	511K	1.39M	2.1M	12.87M	7.29M	14.2M	11.83M
Total Debt+	0	0	0	0	90K	293K	236K	139K	0	0
Net Debt	-31.3M	-18.71M	-10.48M	-19.81M	-22.99M	-93.21M	-233.2M	-200.88M	-121.14M	-128.57M
Debt / Equity	-	-	-	-	0.00x	0.00x	0.00x	0.00x	-	-
Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-
Interest Coverage	-	-	-	-	-	-	-	-	-	-
Total Equity+	29.37M	18.64M	9.7M	19.63M	22.1M	92.2M	253.91M	227.54M	137.47M	145.7M
Equity Growth %	-0.27%	-0.37%	-0.48%	1.02%	0.13%	3.17%	1.75%	-0.1%	-0.4%	0.06%
Book Value per Share	4.49	2.86	1.48	1.84	1.27	3.53	6.44	5.66	3.28	3.13
Total Shareholders' Equity	29.37M	18.64M	9.7M	19.63M	22.1M	92.2M	253.91M	227.54M	137.47M	145.7M
Common Stock	46K	46K	7K	17K	22K	35K	40K	42K	42K	48K
Retained Earnings	-130.64M	-145.49M	-157.4M	-163.96M	-168.59M	-174.92M	-207.31M	-283.55M	-380.77M	-405.11M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	-700K	-700K	-800K	-900K	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-9.05M	-12.23M	-8.24M	-4.77M	-2.51M	-5.38M	-30.2M	-77.51M	-82.03M	-116.93M
Operating CF Margin %	-	-	-	-	-	-	-	-	-	-
Operating CF Growth %	0.05%	-0.35%	0.33%	0.42%	0.47%	-1.14%	-4.61%	-1.57%	-0.06%	-0.43%
Net Income	-14.14M	-14.85M	-11.91M	-6.56M	-4.63M	-6.33M	-32.38M	-76.25M	-97.22M	-24.34M
Depreciation & Amortization	45K	58K	68K	69K	58K	22K	534K	1.3M	1.53M	1.13M
Stock-Based Compensation	3.46M	4.33M	2.97M	2.39M	0	988K	1.76M	2.07M	0	16.29M
Deferred Taxes	0	0	0	0	0	0	3.39M	-8.12M	0	0
Other Non-Cash Items	-4K	-8K	-2K	2.66M	1.3M	-346K	-3.39M	8.12M	4.59M	-108.18M
Working Capital Changes	1.59M	-1.77M	635K	-670K	763K	288K	-104K	-4.63M	9.08M	-1.83M
Change in Receivables	0	0	0	0	0	0	0	0	0	0
Change in Inventory	0	0	0	0	0	0	0	0	0	0
Change in Payables	841K	-711K	129K	-130K	159K	458K	6.21M	-3.45M	6.9M	-2.92M
Cash from Investing+	-192K	-2.17M	2.1M	0	-18K	360K	-22.21M	-2.71M	-414K	-103K
Capital Expenditures	-195K	-75K	0	0	-18K	0	-22.21M	-2.71M	-414K	-103K
CapEx % of Revenue	-	-	-	-	-	-	-	-	-	-
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	3	-2.09K	2.1K	0	0	360K	0	0	0	0
Cash from Financing+	-46K	-284K	0	14.1M	5.81M	75.45M	192.34M	47.8M	2.56M	124.47M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	-46K	-284K	0	0	0	256K	2.52M	475K	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-9.25M	-12.31M	-8.24M	-4.77M	-2.53M	-5.38M	-52.41M	-80.23M	-82.44M	-117.03M
FCF Margin %	-	-	-	-	-	-	-	-	-	-
FCF Growth %	0.04%	-0.33%	0.33%	0.42%	0.47%	-1.13%	-8.74%	-0.53%	-0.03%	-0.42%
FCF per Share	-1.41	-1.89	-1.26	-0.45	-0.15	-0.21	-1.33	-2.00	-1.97	-2.51
FCF Conversion (FCF/Net Income)	0.64x	0.82x	0.69x	0.73x	0.54x	0.85x	0.93x	1.02x	0.84x	4.80x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-40.75%	-61.87%	-84.07%	-44.72%	-22.2%	-11.08%	-18.71%	-31.67%	-53.27%	-17.19%
Return on Invested Capital (ROIC)	-	-	-	-	-	-	-250.25%	-253.35%	-369.66%	-634.06%
Debt / Equity	-	-	-	-	0.00x	0.00x	0.00x	0.00x	-	-
FCF Conversion	0.64x	0.82x	0.69x	0.73x	0.54x	0.85x	0.93x	1.02x	0.84x	4.80x

Frequently Asked Questions

Growth & Financials

Cassava Sciences, Inc. (SAVA) grew revenue by 0.0% over the past year. Growth has been modest.

Cassava Sciences, Inc. (SAVA) reported a net loss of $106.0M for fiscal year 2024.

Dividend & Returns

Cassava Sciences, Inc. (SAVA) has a return on equity (ROE) of -17.2%. Negative ROE indicates the company is unprofitable.

Cassava Sciences, Inc. (SAVA) had negative free cash flow of $83.9M in fiscal year 2024, likely due to heavy capital investments.